Regeneron 4th-quarter profit beats on rising Eylea sales
Feb 14 (Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit beat market estimates for the sixth straight quarter as sales of its eye drug Eylea continued to zoom.
The company posted a fourth-quarter net profit of $470 million, or $4.08 per share, compared with a net loss of $53.4 million, or 58 cents per share, a year earlier.
The company's adjusted profit of $1.22 per share, according to Thomson Reuters I/B/E/S, beat analysts' estimates of $1.10 per share.
Total revenue for the quarter more than tripled to $414.6 million.
Eylea, which is co-marketed by Germany's Bayer AG , raked in U.S. sales of $276 million.
Analysts expected revenue of $392.6 million.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Target cyber breach hits 40 million payment cards at holiday peak |
- Pizza outlet attacked as India, U.S. fail to cool diplomat row |
- New York Mayor-elect's reputation for lateness parodied on Twitter
- Putin critic Khodorkovsky free after pardon, heads for Germany |